Long-term efficacy of 90Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 1985-1992

  Andrade Campos, Marcio Miguel ^a,b   Montes Limón, Anel E ^a   Soro Alcubierre, Gloria ^a   Grasa, José María ^a   Lopez Gómez, Luis ^c   Baringo, Teresa ^a   Giraldo, Pilar ^a,b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Royo Villanova Hospital   (Spain)

Author keywords

Health related quality of Life; Non Hodgkin lymphoma; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR ANTIGEN; YTTRIUM;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; NEUTROPENIA; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; REMISSION; THROMBOCYTOPENIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; NEUTROPENIA; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; THROMBOCYTOPENIA; YTTRIUM RADIOISOTOPES;

EID: 84922260262     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2145-6     Document Type: Article

References (24)

1. Leukemia and Lymphoma Society. Facts 2012. Statistics Review. (2012) http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmterial/generalcancer/pdf/facts.pdf. Accessed 22 April 2014
2. The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909
3. Hoffman R, Furie B, Benz EJ, McGlave P, Silberstein LE, Shattil S (2009) Basic principles and practice of hematology, 5th edn. ED Elsevier, Amsterdam
4. Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II lowgrade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282–1290
5. Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159
6. Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M. Watchful waiting in low–tumor burden follicular lymphoma in the rituximab era: Results of an F2-Study Database JCO JCO.2010.33.4474; published online on September 24, 2012
7. Jacobson CA, Freedman AS (2012) Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol 24(5):475–479
8. Press OW (1999) Review radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 26(5 Suppl 14):58–65
9. Illidge T, Morschhauser F (2011) Radioimmunotherapy in follicular lymphoma. Best Pract Res 24(2):279–293
10. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463
11. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, D’Amore F, Gonzalez GM, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164
12. Andrade Campos MM, Montes Limón AE, Grasa JM, Lievano P, Baringo T, Giraldo P. RIT with Y90-Ibritumomab Tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution. J Oncol. 2012;2012:412742. Epub 2012 Sep 25
13. Illdge TM (2010) Radioimmunotherapy of lymphomas: a treatment approach ahead of its time or past its sell by date? J Clin Oncol 28:2944–2946
14. Tennvall J, Fischer M, Bischof Delaloye A et al (2007) EANM procedure guideline for radio-immunotheapy for B-cell lymphoma with 90Y-radiolabelled ibritumumab tiuxetan (Zevalin®). Eur J Nucl Med 48:1767–1776
15. Jacene HA, Filice R, Kasecam W, Wahl R (2009) 18 F-DG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50:8–17
16. Pyo J, Kim KW, Jacene HA, Sakellis C, Brown J, Abbeele V d (2013) A end-therapy positron emission tomography for treatment response assesment in folicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res 19:6566–6577
17. Aaronson NK, Acquadro C, Alonso J et al (1992) International quality of life assessment (IQOLA) project. Quall IFE rES 1:349–351
18. Alonso J, Prieto L, Antó JM (1995) La Version española del SF-36 health survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados. Med Clin (Barc) 104:771–776
19. Costa-Requena G, Gil F. Quality of life in the chemotherapy treatment of Spanish cancer patients: a comparison of general population norms
20. Herce-Lopez J, Rollon-Mayordomo A, Lozano-Rosado R, Infante-Cossio P, Salazar-Fernandez CI. Assessment of quality of life of oral cancer survivors compared with Spanish populations norms
21. Lowry L, Ardeshna KM (2012) Has single-agent rituximab replaced watch-and-wait for patient with asymptomatic low-grade follicular lymphoma? Cancer J 18(5):390–395
22. Rose AC, Shenoy PJ, Garett G et al (2012) A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 12(6):393–399
23. Mourschhauser F, Radford J, Van Hoof A, et al.: 90Ytrium-Ibritumomab Tiuxetan Consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent Trial. J Clin Oncol 2013 Published ahead of print on April 1, 2013 JCO.2012.45.6400
24. Hohloch K, Bischof Delaloye A, Windemuth-Kiesselbach C et al (2011) Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunothrapy network. J Nucl Med 52:1354–1360